About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
MAbs
›
top-articles
MAbs
5.1
(top 5%)
impact factor
1.4K
(top 20%)
papers
54.9K
(top 5%)
citations
104
(top 5%)
h
-index
5.2
(top 5%)
impact factor
1.6K
all documents
59.4K
doc citations
162
(top 5%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
The therapeutic monoclonal antibody market
MAbs
2015
1,049
2
The making of bispecific antibodies
MAbs
2017
626
3
The immunogenicity of humanized and fully human antibodies
MAbs
2010
569
4
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
MAbs
2009
554
5
Site-specific antibody drug conjugates for cancer therapy
MAbs
2014
547
6
Cell culture processes for monoclonal antibody production
MAbs
2010
540
7
Recovery and purification process development for monoclonal antibody production
MAbs
2010
416
8
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
MAbs
2015
405
9
Antibodies to watch in 2019
MAbs
2019
387
10
Antibodies to watch in 2020
MAbs
2020
381
11
Antibody fragments
MAbs
2010
370
12
Dual targeting strategies with bispecific antibodies
MAbs
2012
362
13
Charge variants in IgG1
MAbs
2010
350
14
Disulfide bond structures of IgG molecules
MAbs
2012
347
15
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
MAbs
2016
340
16
Marketed therapeutic antibodies compendium
MAbs
2012
320
17
Analytical methods for physicochemical characterization of antibody drug conjugates
MAbs
2011
298
18
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
MAbs
2013
280
19
Phage display-derived human antibodies in clinical development and therapy
MAbs
2016
263
20
Bispecific antibodies for cancer therapy
MAbs
2009
260
21
Fragmentation of monoclonal antibodies
MAbs
2011
258
22
Discovery and mechanism of ustekinumab
MAbs
2011
246
23
The impact of glycosylation on monoclonal antibody conformation and stability
MAbs
2011
241
24
Antibodies to watch in 2022
MAbs
2022
239
25
Antibodies to watch in 2021
MAbs
2021
237
26
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data
MAbs
2011
235
27
Antibodies to watch in 2017
MAbs
2017
225
28
Macrophages are critical effectors of antibody therapies for cancer
MAbs
2015
223
29
Antibodies to watch in 2018
MAbs
2018
223
30
Catumaxomab
MAbs
2010
218
31
The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
MAbs
2018
215
32
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
MAbs
2010
214
33
Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies
MAbs
2012
214
34
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
MAbs
2010
213
35
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
MAbs
2013
213
36
ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation
MAbs
2016
208
37
Antibody-based therapeutics to watch in 2011
MAbs
2011
207
38
Canakinumab
MAbs
2010
203
39
Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
MAbs
2010
201
40
A strategy for risk mitigation of antibodies with fast clearance
MAbs
2012
200
41
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
MAbs
2009
195
42
Neonatal Fc receptor and IgG-based therapeutics
MAbs
2011
194
43
Marketing approval of mogamulizumab
MAbs
2012
193
44
Human immunoglobulin allotypes
MAbs
2009
187
45
Structure, heterogeneity and developability assessment of therapeutic antibodies
MAbs
2019
186
46
A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties
MAbs
2013
183
47
Antibody biodistribution coefficients
MAbs
2013
177
48
Affinity of human IgG subclasses to mouse Fc gamma receptors
MAbs
2017
175
49
Potential aggregation prone regions in biotherapeutics
MAbs
2009
173
50
Physicochemical characterization of Remsima®
MAbs
2014
173
site/software ©
exaly
; All materials licenced under
CC by-SA
.